Traditional Chinese medicine composition for treating Alzheimer disease as well as preparation method and application of traditional Chinese medicine composition

Through the effects of Chinese medicine composition tonifying the kidney, relieving phlegm, promoting blood circulation and relieving fire, the problems of large side effects, low efficacy and short effective time in the treatment of Alzheimer's disease are solved, which significantly improves the patient's learning and memory ability and extends the patient's Treatment is effective and fills the gap in early treatment.

CN119055736APending Publication Date: 2024-12-03HEFEI JINSIWEI PHARMACEUTICAL TECHNOLOGY CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202310648010.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-02
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing Alzheimer's disease treatment drugs have problems such as large side effects, low efficacy and short effective time, especially in the absence of effective treatment options for early and mid-stage patients.

Method used

A Chinese medicine composition is adopted, including ginseng, rehmannia, Cornus officinalis, Cuscuta, Morinica, wolfberry, fried jujube seed, pearl powder, acorus granulated, Poria and turmeric, and other ingredients to nourish the kidney, resolve phlegm, and activate blood circulation. and the effect of fire relief is used to treat Alzheimer's disease, and it is made into a variety of dosage forms such as granules, pills, etc., which are used to prevent and treat Alzheimer's disease.

Benefits of technology

This traditional Chinese medicine composition significantly improves the learning and memory ability of patients with Alzheimer's disease, extends the effective time of treatment, reduces side effects, fills the gap in early Alzheimer's disease treatment, and improves the cognition of patients with dementia period Function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004264011410000091
    Figure BDA0004264011410000091
  • Figure BDA0004264011410000101
    Figure BDA0004264011410000101
  • Figure BDA0004264011410000112
    Figure BDA0004264011410000112
Patent Text Reader

Abstract

The invention discloses a traditional Chinese medicine composition for treating Alzheimer disease as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw materials in parts by mass: 5-15 parts of ginseng, 12-35 parts of prepared rehmannia root, 9-20 parts of fructus corni, 8-35 parts of semen cuscutae, 8-25 parts of radix morindae officinalis, 6-15 parts of fructus lycii, 9-20 parts of fried semen ziziphi spinosae, 0.1-0.7 part of pearl powder, 5-12 parts of rhizoma acori graminei, 6-15 parts of poria with hostwood, 5-12 parts of rhizoma curcumae longae and 2-8 parts of rhizoma coptidis. Compared with a model group, the composition for treating the Alzheimer disease, provided by the invention, has the advantages that in a high-dose group, the learning ability and the memory ability (P is less than 0.05) of mice with learning and memory disorders induced by scopolamine can be improved, and the learning ability and the memory ability (P is less than 0.05, and P is less than 0.01) of rats with the Alzheimer disease caused by injection of Abeta1-42 in bilateral hippocampal CA1 regions.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a traditional Chinese medicine composition for treating Alzheimer's disease and a preparation method and application thereof, belonging to the field of traditional Chinese medicine composition preparations. Background Art

[0002] Alzheimer's disease (AD) is a neurodegenerative disease with an insidious onset and progressive development. Its main clinical features are cognitive impairment, mental and behavioral abnormalities, and decreased social function. Generally, it is early-onset before the age of 65, and late-onset after the age of 65. Familial Alzheimer's disease is called familial Alzheimer's disease, and sporadic Alzheimer's disease is called no family tendency. According to the World Health Organization, there are currently about 50 million people suffering from dementia worldwide, of which Alzheimer's disease is the most common type.

[0003] The pathological changes in the brain of patients with Alzheimer's disease are diffuse brain atrophy, and the microscopic pathological changes are mainly characterized by senile plaques, neurofibrillary tangles and neuron reduction. The center of senile plaques is β-amyloid protein, and the main component of neurofibrillary tangles is highly phosphorylated microtubule-associated protein, namely tau protein. In the onset of Alzheimer's disease, heredity is one of the main factors. At present, there are four genes related to Alzheimer's disease, namely amyloid precursor protein gene, presenilin 1 gene, presenilin 2 gene and apolipoprotein E gene. Among them, mutations or polymorphisms of the first three genes are closely related to early-onset familial Alzheimer's disease, and apolipoprotein E is closely related to sporadic Alzheimer's disease. The currently recognized pathogenesis of Alzheimer's disease believes that the imbalance of the production and clearance of β-amyloid protein is the initiating factor of neuronal degeneration and dementia, which can induce a series of pathological processes such as tau protein hyperphosphorylation, inflammatory response, and neuronal death. At the same time, there are widespread neurotransmitter abnormalities in the brains of Alzheimer's patients, including the acetylcholine system, monoamine system, amino acids and neuropeptides.

[0004] Since the etiology and pathogenesis of Alzheimer's disease are unclear, there is no specific treatment. Most of the approved drugs are single-target drugs: cholinesterase inhibitors (donepezil, rivastigmine, galantamine, etc.) and glutamate receptor antagonists (memantine). However, there are many disadvantages of Western medicine in the treatment of Alzheimer's disease. (1) Western medicine treatment often has large side effects and adverse reactions, and long-term use leads to liver and kidney toxicity; (2) Western medicine treatment can only improve symptoms in the short term, but cannot improve the onset and course of Alzheimer's disease, and the efficacy level is low; (3) Western medicine treatment of Alzheimer's disease is short-lived.

[0005] Therefore, there is an urgent need for an effective drug preparation that can effectively prevent and treat Alzheimer's disease and has few side effects. Summary of the invention

[0006] The purpose of the present invention is to provide a Chinese medicine composition for treating Alzheimer's disease, which has good efficacy in preventing and treating Alzheimer's disease and is highly safe, and effectively solves the problem that current Western medicine treatments often have large side effects and many adverse reactions.

[0007] The Chinese medicine composition of the present invention mainly comprises kidney-tonifying drugs, and is superimposed with drugs for resolving phlegm, promoting blood circulation and purging fire, and is suitable for Alzheimer's disease, has obvious advantages in compatibility, and is different from the existing formula for simply tonifying the kidney.

[0008] The Chinese medicine composition for treating Alzheimer's disease provided by the present invention is prepared from the following raw materials in parts by weight:

[0009] 5-15 parts of ginseng, 12-35 parts of rehmannia root, 9-20 parts of cornus fruit, 8-35 parts of dodder seed, 8-25 parts of eucommia barbarum, 6-15 parts of wolfberry, 9-20 parts of stir-fried spiny jujube kernel, 0.1-0.7 parts of pearl powder, 5-12 parts of calamus, 6-15 parts of poria, 5-12 parts of turmeric, and 2-8 parts of coptis root.

[0010] In the Chinese medicine composition of the present invention, ginseng nourishes the five internal organs, especially the kidney's vital energy, strengthens the will and improves intelligence, and is the main medicine. Radix Rehmanniae Preparata, Morinda Officinalis, Cuscuta Semen, Fructus Corni, and Fructus Lycii nourish the kidney and produce essence, and help ginseng strengthen the will; Acorus Gramineus and Poria strengthen the spleen and resolve phlegm, and help ginseng improve intelligence, and are all ministerial medicines. Semen Ziziphi Spinosae nourishes the liver and restrains the soul, Curcuma Longa enters the liver meridian, promotes blood circulation and calms the soul, and Coptis chinensis and pearl powder also enter the liver meridian, purges fire and calms the soul, and are all adjuvants. All the medicines are used together to play the role of strengthening will, improving intelligence, and calming the soul, and are used for amnesia or forgetfulness caused by kidney deficiency, slow reaction, soreness of waist and knees, dizziness and tinnitus, frequent urination at night, even urinary incontinence, deep and weak pulse, especially two feet, etc., and have a significant therapeutic effect on Alzheimer's disease.

[0011] The mass composition of the Chinese medicine composition of the present invention is preferably:

[0012] 5-12 parts of ginseng, 12-30 parts of rehmannia root, 9-18 parts of cornus fruit, 8-30 parts of dodder seed, 8-22 parts of eucommia barbarum, 6-15 parts of wolfberry, 9-15 parts of stir-fried spiny jujube kernel, 0.1-0.6 parts of pearl powder, 5-9 parts of calamus, 6-12 parts of poria, 5-10 parts of turmeric, and 2-6 parts of coptis root.

[0013] The mass composition of the Chinese medicine composition of the present invention is further preferably:

[0014] 6-10 parts of ginseng, 15-30 parts of rehmannia root, 10-15 parts of cornus fruit, 10-30 parts of dodder seed, 9-20 parts of eucommia barbarum, 9-12 parts of wolfberry, 9-10 parts of stir-fried spiny jujube seeds, 0.2-0.5 parts of pearl powder, 6 parts of calamus, 6-9 parts of poria, 6-9 parts of turmeric, and 3 parts of coptis root.

[0015] The mass composition of the Chinese medicine composition of the present invention is further preferably any one of the following 1)-5):

[0016] 1) 5 parts of ginseng, 12 parts of Rehmannia root, 9 parts of Cornus officinalis, 8 parts of Cuscuta seed, 8 parts of Morinda officinalis, 6 parts of Lycium barbarum, 9 parts of stir-fried Semen Ziziphi Spinosae, 0.1 parts of pearl powder, 5 parts of Acorus calamus, 6 parts of Poria root, 5 parts of Curcuma longa, 2 parts of Coptis chinensis;

[0017] 2) 6 parts of ginseng, 15 parts of Rehmannia root, 10 parts of Cornus officinalis, 10 parts of Cuscuta seed, 9 parts of Morinda officinalis, 9 parts of Lycium barbarum, 9 parts of stir-fried Ziziphus jujuba seeds, 0.2 parts of pearl powder, 6 parts of Acorus calamus, 6 parts of Poria, 6 parts of Curcuma longa, 3 parts of Coptis chinensis;

[0018] 3) 10 parts of ginseng, 30 parts of Rehmannia root, 15 parts of Cornus officinalis, 30 parts of Cuscuta seed, 20 parts of Morinda officinalis, 12 parts of Lycium barbarum, 10 parts of stir-fried Semen Ziziphi Spinosae, 0.5 parts of pearl powder, 6 parts of Acorus calamus, 9 parts of Poria, 9 parts of Curcuma longa, 3 parts of Coptis chinensis;

[0019] 4) 12 parts of ginseng, 30 parts of Rehmannia root, 18 parts of Cornus officinalis, 30 parts of Cuscuta seed, 22 parts of Morinda officinalis, 15 parts of Lycium barbarum, 15 parts of stir-fried Semen Ziziphi Spinosae, 0.6 parts of pearl powder, 9 parts of Acorus calamus, 12 parts of Poria, 10 parts of Curcuma longa, and 6 parts of Coptis chinensis;

[0020] 5) 15 parts of ginseng, 35 parts of prepared rehmannia root, 20 parts of cornus fruit, 35 parts of dodder seed, 25 parts of eucommia barbata, 15 parts of wolfberry, 20 parts of stir-fried spiny jujube seeds, 0.7 parts of pearl powder, 12 parts of calamus, 15 parts of poria, 12 parts of turmeric, and 8 parts of coptis root.

[0021] The Chinese medicine composition of the present invention can be prepared into clinically acceptable dosage forms such as granules, pills, mixtures, decoctions, syrups, decoctions, capsules or tablets.

[0022] The present invention also provides a method for preparing the Chinese medicine composition, comprising the following steps:

[0023] S1, boiling Acorus calamus with water, collecting volatile oil, adding β-cyclodextrin aqueous solution for inclusion to obtain volatile oil inclusion compound; filtering the residue to obtain liquid A;

[0024] S2, extracting ginseng and turmeric with an ethanol solution to obtain an ethanol extract B and medicinal residues;

[0025] S3, combining Radix Rehmanniae Preparata, Fructus Corni, Semen Cuscutae, Fructus Morindae Officinalis, Fructus Lycii, stir-fried Semen Ziziphi Spinosae, Poria, Rhizoma Coptidis with the residues obtained in step S2, then decocting with water, filtering to obtain a filtrate, and concentrating the filtrate to obtain a water extract C;

[0026] S4, the water extract C, the alcohol extract B and the medicinal solution A are combined and concentrated to obtain a concentrated solution D; the concentrated solution D is obtained by any one of the following steps 1)-3):

[0027] 1) mixing the concentrated solution D with the volatile oil inclusion compound and pearl powder to obtain a decoction or a decoction paste;

[0028] 2) The concentrated solution D is mixed with the volatile oil, pearl powder and auxiliary materials to obtain a syrup or a mixture;

[0029] 3) The concentrated liquid D is dried, or dried after adding auxiliary materials, to obtain dry paste powder; the dry paste powder is mixed with the volatile oil inclusion compound and pearl powder, and auxiliary materials are added to obtain granules, capsules, tablets or pills.

[0030] In step S1, the amount of water used is 10 to 20 times the mass of the Acorus calamus;

[0031] In step S2, the volume fraction of the ethanol solution is 50-80%, and the amount thereof is 6-12 times the total mass of the ginseng and the turmeric;

[0032] In step S3, the amount of water is 6 to 12 times the total amount of the Radix Rehmanniae Preparata, the Fructus Corni, the Semen Cuscutae, the Fructus Morindae Officinalis, the Fructus Lycii, the stir-fried Semen Ziziphi Spinosae, the Poria, the Rhizoma Coptidis and the medicinal residues;

[0033] In step S4, the relative density of the concentrated solution D is 1.03-1.20.

[0034] The use of the traditional Chinese medicine composition in the preparation of drugs for preventing and / or treating Alzheimer's disease also falls within the protection scope of the present invention.

[0035] Based on the Chinese medicine composition, the present invention also provides a drug for preventing and / or treating Alzheimer's disease, which uses the Chinese medicine composition as an active ingredient.

[0036] The composition provided by the present invention has the functions of tonifying the kidney and strengthening the will, and also removing phlegm, activating blood circulation and purging fire. It is mainly used to treat Alzheimer's disease, which belongs to kidney deficiency, or combined with phlegm and blood stasis, and the symptoms are forgetfulness, dementia, soreness of waist and knees, frequent urination at night, weak pulse on the radial side, or accompanied by insomnia, hallucination, irritability, etc. Compared with the existing prescriptions, the drug compatibility of the present invention has ginseng, Radix Rehmanniae Preparata, Fructus Lycii, Morinda Officinalis, Semen Cuscutae, Fructus Corni to tonify the kidney and strengthen the will, and Acorus Gramineus to remove phlegm to improve intelligence, and also compatibility with Poria to strengthen the spleen and resolve phlegm, to help the intelligence of the above-mentioned drugs, and compatibility with Semen Ziziphi Spinosae to nourish the liver and gather the soul, Rhizoma Curcumae to promote blood circulation and soothe the soul, Rhizoma Coptis and pearl powder to purge fire and calm the soul, to assist the soothing soul of the above-mentioned drugs. Therefore, the prescription of the present invention can not only be used for forgetfulness and dementia of Alzheimer's disease in terms of indications, but also can be used for mental behavioral symptoms such as insomnia, hallucination, irritability, etc. This is significantly different from other existing formulas.

[0037] Since Alzheimer's disease is a continuous spectrum of symptoms, compared with existing commonly used Western medicines and Chinese medicines, the advantages of the Chinese medicine composition of the present invention are reflected in the following two aspects:

[0038] First of all, the present invention will fill the gap of no drugs available in the very early stage of Alzheimer's disease (i.e. mild cognitive impairment of Alzheimer's disease), because there is currently no approved therapeutic drug for the very early stage of Alzheimer's disease. The cholinesterase inhibitors (ChEIs) that have been on the market are mainly used for the dementia stage of Alzheimer's disease. Clinical trials have shown that ChEIs have no benefit or reduction in the progression of Alzheimer's disease from the amnesia stage (MCI) to the dementia stage (Neurology 2018, 90: 1-10). The present invention uses kidney-tonifying and will-strengthening drugs as the main ingredients, which can fill the gap of no drugs available in the very early stage of Alzheimer's disease.

[0039] Secondly, the present invention will make up for and replace the deficiencies of conventional western medicines for Alzheimer's dementia. Currently, there are two types of conventional western medicines: one is symptomatic therapy, which targets neurochemistry, among which ChEIs are only effective for 9 months for early and middle-stage Alzheimer's dementia and cannot delay disease progression (BMC Neurol 2014, 14: 173-9); memantine is only effective for 3 months for middle and late-stage Alzheimer's dementia (N Engl J Med 2012, 366 (10): 893-903.), and there is a lack of effective evidence for early or middle-stage Alzheimer's dementia (Arch Neurol 2011, 68 (8): 991-998.). For Alzheimer's dementia with psychiatric and behavioral symptoms such as hallucinations or agitation, any atypical antipsychotic drug for more than 2 weeks will aggravate cognitive impairment. The degree of cognitive impairment after 36 weeks of treatment is equivalent to the natural deterioration of Alzheimer's disease in one year, and the incidence and mortality of severe cerebrovascular events and extrapyramidal symptoms are significantly increased (Am J Psychiatry 2011, 168 (8): 831-839.). The other type is modification therapy, which targets Aβ protein, and 17 drugs have entered Phase III trials. Among them, a marine brown algae extract was conditionally approved for marketing in my country (Alzheimers Res Ther 2021, 13: 62), but has not yet completed post-marketing re-evaluation (Phase IV), which means that its efficacy has not been fully verified. Another Aβ42 monoclonal antibody has not yet brought cognitive and functional benefits to patients with mild Alzheimer's disease since it was approved in the United States. The two major US medical insurance systems have decided not to include it in the prescription set and routine clinical practice (JAMA Intern Med 2021, 325(17): 1717-1718). A recently approved Aβ protofibril antibody for the treatment of early Alzheimer's disease also did not meet the clinically significant minimum difference value, i.e., the effectiveness standard (CDR-SB reduction -0.9) (N Engl J Med 2023, 388: 9-21).

[0040] Based on the above analysis, the current conventional western medicines for Alzheimer's dementia have three shortcomings: first, the effective time is short, second, the efficacy level is low, and third, the toxic side effects are large. The potential advantages of the present invention are: (1) filling the gap of no medicine available in the very early stage of Alzheimer's disease, (2) supplementing the shortcomings of the short effective time of the treatment drugs for the dementia stage of Alzheimer's disease and the aggravation of cognitive impairment by atypical antipsychotic drugs and other patented prescriptions ignoring the symptoms of mental behavior, (3) combined with conventional western medicine, it is expected to prolong the effective time of the treatment of the dementia stage of Alzheimer's disease.

[0041] Compared with the model group, the high-dose group of the composition for treating Alzheimer's disease provided by the present invention can improve the learning ability and memory ability of mice with learning and memory impairment induced by scopolamine (P < 0.05), and improve the bilateral hippocampal CA1 region injection of Aβ 1-42 The learning and memory abilities of rats with Alzheimer's disease were affected by the drug (P<0.05, P<0.01). DETAILED DESCRIPTION

[0042] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0043] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0044] Preparation Example

[0045] Embodiment 1,

[0046] Prescription: 6 parts of ginseng, 15 parts of Rehmannia root, 10 parts of Cornus officinalis, 10 parts of Cuscuta seed, 9 parts of Morinda officinalis, 9 parts of Lycium barbarum, 9 parts of stir-fried Ziziphus jujuba seeds, 0.2 parts of pearl powder, 6 parts of Acorus calamus, 6 parts of Poria, 6 parts of Curcuma longa, and 3 parts of Coptis chinensis.

[0047] Preparation method:

[0048] Step 1, take the above-mentioned Acorus calamus in parts by weight, add 20 times the weight of water to boil, extract volatile oil, filter the residue, obtain liquid A, and set aside.

[0049] Step 2, adding volatile oil dropwise to the β-cyclodextrin aqueous solution, stirring for 2 hours, leaving at room temperature for 24 hours, filtering, and drying the precipitate at below 70° C. to obtain a volatile oil β-cyclodextrin inclusion complex, crushing it into fine powder for later use;

[0050] Step 3, take the above-mentioned weight portions of ginseng, rehmannia root, cornus fruit, dodder seed, Morinda officinalis, wolfberry fruit, stir-fried spiny jujube seed, poria, turmeric, coptis root and the residue of step 1, add 10 times the weight of water, decoct twice, each time for 1.5 hours, filter, concentrate the filtrate, combine it with the medicinal solution A and continue to concentrate, dry or add auxiliary materials (dextrin, lactose, microcrystalline cellulose) to dry, crush, mix with the volatile oil inclusion compound obtained in step 2 and the above-mentioned weight portions of pearl powder, add auxiliary materials (dextrin, lactose, microcrystalline cellulose) and mix to make granules.

[0051] Embodiment 2,

[0052] Prescription: 12 parts of ginseng, 30 parts of Rehmannia root, 18 parts of Cornus officinalis, 30 parts of Cuscuta seed, 22 parts of Morinda officinalis, 15 parts of Lycium barbarum, 15 parts of stir-fried Ziziphus jujuba seeds, 0.6 parts of pearl powder, 9 parts of Acorus calamus, 12 parts of Poria root, 10 parts of Curcuma longa, and 6 parts of Coptis chinensis.

[0053] Preparation method:

[0054] Step 1, take the above-mentioned Acorus calamus in parts by weight, add 15 times the weight of water to boil, extract volatile oil, filter the residue, obtain liquid A, and set aside.

[0055] Step 2, adding volatile oil dropwise to the β-cyclodextrin aqueous solution, stirring for 2 hours, leaving at room temperature for 24 hours, filtering, and drying the precipitate at below 70° C. to obtain a volatile oil β-cyclodextrin inclusion complex, crushing it into fine powder for later use;

[0056] Step 3, take the above-mentioned weight portions of ginseng, Rehmannia root, Cornus officinalis, Cuscuta australis, Morinda officinalis, Lycium barbarum, stir-fried Ziziphus jujuba seeds, Poria root, Curcuma longa, and Coptis chinensis, add 10 times the weight of water, decoct twice, each time for 1.5 hours, filter, concentrate the filtrate, combine it with the medicinal solution A and continue to concentrate, dry or add auxiliary materials (dextrin, lactose, microcrystalline cellulose) to dry, crush, mix with the volatile oil inclusion compound obtained in step 2 and the above-mentioned weight portions of pearl powder, add auxiliary materials (dextrin, lactose) and mix to make granules.

[0057] Embodiment 3,

[0058] Prescription: 5 parts of ginseng, 12 parts of Rehmannia root, 9 parts of Cornus officinalis, 8 parts of Cuscuta seed, 8 parts of Morinda officinalis, 6 parts of Lycium barbarum, 9 parts of stir-fried Ziziphus jujuba seeds, 0.1 parts of pearl powder, 5 parts of Acorus calamus, 6 parts of Poria root, 5 parts of Curcuma longa, and 2 parts of Coptis chinensis.

[0059] Preparation method:

[0060] Step 1, take the above-mentioned Acorus calamus in parts by weight, add 20 times the weight of water to boil, extract volatile oil, filter the residue, obtain liquid A, and set aside.

[0061] Step 2, adding volatile oil dropwise to the β-cyclodextrin aqueous solution, stirring for 2 hours, leaving at room temperature for 24 hours, filtering, and drying the precipitate at below 70° C. to obtain a volatile oil β-cyclodextrin inclusion complex, crushing it into fine powder for later use;

[0062] Step 3, take the above-mentioned weight portions of ginseng, Rehmannia root, Cornus officinalis, Cuscuta seed, Morinda officinalis, Lycium barbarum, stir-fried Ziziphus jujuba seeds, Poria, Curcuma longa, and Coptis chinensis, add 10 times the weight of water, decoct twice, each time for 1.5 hours, filter, concentrate the filtrate, combine with liquid A and continue to concentrate to a relative density of 1.03 to 1.20, add ethanol while stirring to make the alcohol content reach 60%, stand at room temperature or refrigerate for 36 hours, filter the supernatant, recover the ethanol until there is no alcohol taste, dry or add auxiliary materials (dextrin, lactose, microcrystalline cellulose) to dry, and obtain extract C;

[0063] Step 4, mix the extract C with the volatile oil inclusion compound and the pearl powder in the above weight proportion, and add auxiliary materials (dextrin, lactose, microcrystalline cellulose) to prepare pills.

[0064] Embodiment 4,

[0065] Prescription: 10 parts of ginseng, 30 parts of Rehmannia root, 15 parts of Cornus officinalis, 30 parts of Cuscuta seed, 20 parts of Morinda officinalis, 12 parts of Lycium barbarum, 10 parts of stir-fried Ziziphus jujuba seeds, 0.5 parts of pearl powder, 6 parts of Acorus calamus, 9 parts of Poria, 9 parts of Curcuma longa, and 3 parts of Coptis chinensis.

[0066] Preparation method:

[0067] Step 1, take the above-mentioned Acorus calamus in parts by weight, add 20 times the weight of water to boil, extract volatile oil, filter the residue, obtain liquid A, and set aside.

[0068] Step 2, adding volatile oil dropwise to the β-cyclodextrin aqueous solution, stirring for 2 hours, leaving at room temperature for 24 hours, filtering, and drying the precipitate at below 70° C. to obtain a volatile oil β-cyclodextrin inclusion complex, crushing it into fine powder for later use;

[0069] Step 3, take the above weight portions of ginseng and turmeric, add 12 times the weight of 60% ethanol, extract twice, each time for 2 hours, filter, and set aside the residue; recover ethanol from the filtrate until there is no alcohol taste, and obtain liquid B, which is set aside.

[0070] Step 4, taking the above-mentioned weight portions of Rehmannia glutinosa, Fructus Corni, Cuscuta chinensis, Morinda officinalis, Fructus Lycii, stir-fried Semen Ziziphi Spinosae, Poria cocos, and Rhizoma Coptidis, and combining them with the ginseng and turmeric residues of step 3, adding 12 times the weight of water, decocting twice, each time for 1.5 hours, filtering, concentrating the filtrate, combining it with the medicinal solution A of step 1 and the medicinal solution B of step 3 while continuing to concentrate, and drying or adding auxiliary materials (dextrin, lactose, microcrystalline cellulose) to dry, to obtain extract C;

[0071] Step 5, mix the extract C with the volatile oil inclusion compound and the pearl powder in the above weight proportion, and add auxiliary materials (dextrin, lactose, microcrystalline cellulose) to prepare capsules.

[0072] Embodiment 5,

[0073] Prescription: 15 parts of ginseng, 35 parts of Rehmannia root, 20 parts of Cornus officinalis, 35 parts of Cuscuta seeds, 25 parts of Morinda officinalis, 15 parts of Lycium barbarum, 20 parts of stir-fried Ziziphus jujuba seeds, 0.7 parts of pearl powder, 12 parts of Acorus calamus, 15 parts of Poria root, 12 parts of Curcuma longa, and 8 parts of Coptis chinensis.

[0074] Preparation method:

[0075] Step 1, take the above-mentioned Acorus calamus in parts by weight, add 10 times the weight of water to boil, extract volatile oil, filter the residue, obtain liquid A, and set aside.

[0076] Step 2, adding volatile oil dropwise to the β-cyclodextrin aqueous solution, stirring for 2 hours, leaving at room temperature for 24 hours, filtering, and drying the precipitate at below 70° C. to obtain a volatile oil β-cyclodextrin inclusion complex, crushing it into fine powder for later use;

[0077] Step 3, take the above-mentioned weight portions of ginseng and turmeric, add 10 times the weight of 65% ethanol, extract three times, each time for 1.5 hours, filter, and set aside the residue; recover ethanol from the filtrate until there is no alcohol taste, and obtain liquid B, which is set aside.

[0078] Step 4, taking the above-mentioned weight portions of Rehmannia glutinosa, Fructus Corni, Cuscuta chinensis, Morinda officinalis, Fructus Lycii, stir-fried Semen Ziziphi Spinosae, Poria cocos, and Rhizoma Coptidis, and combining them with the ginseng and turmeric residues of step 3, adding 10 times the weight of water, decocting twice, each time for 1.5 hours, filtering, concentrating the filtrate, combining it with the medicinal solution A of step 1, and continuing to concentrate to a relative density of 1.03-1.20, adding ethanol while stirring to make the alcohol content reach 80%, standing at room temperature or refrigerating for 48 hours, filtering the supernatant, recovering ethanol until there is no alcohol taste, combining it with the medicinal solution B of step 3, drying or adding auxiliary materials (dextrin, lactose, microcrystalline cellulose) to obtain extract C;

[0079] Step 5, mix the extract C with the volatile oil inclusion compound and the pearl powder in the above-mentioned weight proportion, and add auxiliary materials (dextrin, lactose, microcrystalline cellulose) to prepare granules.

[0080] Effect Example

[0081] Test Example 1

[0082] The following pharmacodynamic test is used to better illustrate the use of the Chinese medicine composition of the present invention in treating Alzheimer's disease.

[0083] Comparison between the composition of the present invention and the control group shows that the composition of the present invention has a good effect in treating Alzheimer's disease.

[0084] The learning and memory disorder model of mice was induced by injection of scopolamine hydrobromide, and the effect of the composition of the present invention on the learning and memory ability of the mice with learning and memory disorders was investigated by Morris water maze experiment.

[0085] 1. Materials

[0086] Drugs and reagents

[0087] High, medium and low dose groups (8.76 g / kg, 4.38 g / kg and 1.46 g / kg) of the composition of Example 4 of the present invention.

[0088] Scopolamine hydrobromide injection: Suicheng Pharmaceutical Co., Ltd., batch number 1701311.

[0089] Donepezil: Eisai (China) Pharmaceutical Co., Ltd., batch number 170624.

[0090] Animals: ICR mice, male, SPF grade, weight 18-22 g, animal certificate number: No1712200002; license: SCXK (Zhejiang) 2014-0001.

[0091] Main instruments and equipment: Morris water maze, Cleversys, USA.

[0092] 2. Methods

[0093] 70 ICR mice, weighing 20±2g, were randomly divided into groups, with 10 mice in each group, namely normal control group, model group, positive group (1 mg / kg of donepezil), low-dose group, medium-dose group and high-dose group of the present composition. The administration volume was 20 ml / kg for each group. The normal control group and the model group were given an equal volume of water, and the administration was once a day. On the 28th day, except for the normal control group, the mice in other groups were subcutaneously injected with 2 mg / kg of scopolamine hydrobromide. At 30min, 24h and 48h after the injection, the learning ability of the mice was measured by Morris water maze; 72h after the injection of scopolamine hydrobromide, the memory ability of the mice was measured by Morris water maze.

[0094] Morris water maze experimental method: First, a positioning navigation experiment was conducted. For 3 consecutive days, mice were placed into the pool from the water entry points of the 4 quadrants facing the pool wall, and the time required for them to successfully find the underwater platform (the platform was placed in the third quadrant) within 90 seconds was measured, that is, the escape latency; if the mouse failed to successfully find the platform within 90 seconds, it was guided to the platform and stayed for 10 seconds, and the escape latency was recorded as 90 seconds. Then a spatial exploration test was conducted, the platform was removed, and the mouse was placed in the water from the midpoint of the pool wall on the opposite side of the original platform (the first quadrant), and the latency and number of times it crossed the platform within 90 seconds were recorded.

[0095] 3. Experimental results

[0096] As shown in Table 1, the middle and high dose groups of the composition of the present invention can significantly promote the learning ability and memory ability of the model mice (P < 0.05).

[0097] Table 1 Effects of different doses of Golden Memory Granules on learning and memory in mice given scopolamine

[0098]

[0099]

[0100] Compared with the model group, * P<0.05

[0101] Test Example 2

[0102] An Alzheimer's disease (AD) rat model was established by injecting Aβ amylase into the CA1 region of the bilateral hippocampus, and the Morris water maze test was used to investigate the effects of the composition of the present invention on the learning and memory abilities of rats with learning and memory disorders.

[0103] 1. Materials

[0104] 1.1 Drugs and reagents

[0105] The composition of the present invention: high, medium and low dose groups of Example 4 (7.02 g / kg, 3.51 g / kg and 1.17 g / kg).

[0106] Aβ 1-42 : MCE Company, before use, the prepared Aβ (concentration: 1ug / uL) was treated at 37℃ for 3 days to allow it to be fully cross-linked.

[0107] Donepezil: Eisai (China) Pharmaceutical Co., Ltd., batch number 1706024.

[0108] 1.2 Animals

[0109] SD rats, male, weight 240-260 g, Jinan Pengyue Experimental Animal Breeding Co., Ltd., license: SCXK(Lu)20140007.

[0110] 1.3. Main instruments and equipment

[0111] Morris water maze, SMART; double-arm digital stereotaxic apparatus: Rayward

[0112] 2 Methods

[0113] 2.1 Grouping and Dosing

[0114] After all rats were adaptively fed for 3 days, a water maze test was performed to screen their learning and memory abilities, and 6 unqualified rats were eliminated. Subsequently, male SD rats were randomly divided into a normal control group, a model group, a positive group (0.5 mg / kg of donepezil), and the composition, with 10 rats in each group. Except for the normal control group, the remaining animals were injected with Aβ amylase in the CA1 region of the hippocampus to establish an Alzheimer's disease (AD) rat model. From the second day of modeling, each group began to receive oral administration, once a day, for 28 consecutive days.

[0115] 2.2 Preparation of Alzheimer's disease (AD) rat model

[0116] Male SD rats were anesthetized by intraperitoneal injection of 10% chloral hydrate (350 mg / kg). After successful anesthesia, the rats were fixed on a brain stereotaxic instrument. A midline incision was made on the top of the head to expose the anterior fontanelle. Referring to the rat brain stereotaxic atlas, the intersection of the anterior fontanelle and the sagittal suture was used as the center, and then a hole was drilled with a No. 10 needle 3.6 mm backward and 2.3 mm on each side. The microinjection needle was inserted vertically through the hole of the stereotaxic instrument into the 5.0 mm below the dura mater, placed in the hippocampal CA1 area, and Aβ was slowly pushed in. 1-425ul, injection speed 1ul / min, let stand for 5min and then slowly withdraw the needle. The normal control group was injected with the same amount of saline in the same location in the same way. After the model was established, the wound was sutured, iodine was wiped and 100,000U of penicillin powder was applied.

[0117] 2.3 Morris water maze test

[0118] The experiment was conducted on the 24th to 28th day. The Morris water maze test procedure is divided into two parts: the navigation test and the space exploration test. Clean water was poured into the pool, and the water surface was 1 cm above the platform. The water temperature was controlled at 24±0.5℃, and the platform was placed in the middle of the IV quadrant of the water maze. One day before the formal experiment, all rats swam freely for 60 seconds to familiarize themselves with the environment.

[0119] Positioning navigation experiment

[0120] The rats were trained once a day for 4 days, each time in 4 rounds. The rats were placed in the water from the same position in quadrants I, II, III, and IV in the same order, facing the wall of the equipment pool. If the rats did not find the platform within 60 seconds, they were guided to the platform and stayed there for 15 seconds. If the rats found the platform within 60 seconds, they were also allowed to stay on the platform for 15 seconds to end the training. The time it took the rats to find the platform within 60 seconds was recorded as the escape latency. This experiment reflects the learning ability of the rats.

[0121] Space exploration experiment

[0122] On the fifth day, the platform was removed and the rat was placed in the water facing the pool wall at the same location in quadrant I. The time the rat spent in the target quadrant and the swimming distance were recorded within 60 seconds.

[0123] 3. Experimental results

[0124] 3.1 Morris water maze positioning and navigation experiment

[0125] As shown in Table 2, compared with the normal control group, the escape latency of the rats in the model group was significantly increased (P < 0.05, P < 0.01); compared with the model group, the escape latency of the rats in the high-dose groups of donepezil and the present composition (2nd, 3rd, 4th day) was significantly reduced (P < 0.05, P < 0.01).

[0126] Table 2 Effects of different doses of gold memory particles on the escape latency of the orientation navigation test in AD model rats

[0127]

[0128]

[0129] Compared with the normal group # P<0.05,## P<0.01; compared with the model group, * P<0.05, ** P<0.01

[0130] As shown in Table 3, compared with the normal group, the total swimming distance of the rats in the model group was significantly increased (4th day, P < 0.05); compared with the model group, on the 4th day, the total swimming distance of the rats in the donepezil group (P < 0.05), the high-dose group of the present composition (P < 0.01) and the medium-dose group (P < 0.01) was significantly reduced.

[0131] Table 3 Effects of different doses of gold memory particles on the total swimming distance in the positioning navigation experiment of AD model rats

[0132]

[0133] Compared with the normal group # P<0.05; compared with the model group, * P<0.05, ** P<0.01

[0134] 3.2 Morris water maze spatial exploration experiment results

[0135] As shown in Table 4, compared with the normal control group, the target quadrant distance and target quadrant time of the rats in the model group were significantly reduced (P < 0.05); compared with the model group, the target quadrant distance of the rats in the high-dose group and the medium-dose group of the present composition was significantly increased (P < 0.05); compared with the model group, the target quadrant time of the rats in the high-dose group of the present composition was significantly increased (P < 0.05).

[0136] Table 4 Effects of different doses of Golden Memory Granules on target quadrant distance and target quadrant time in AD model rats

[0137]

[0138] Compared with the normal group # P<0.05; compared with the model group, * P<0.05

[0139] 4. Experimental conclusion

[0140] The Chinese medicine composition of the present invention has a certain effect of improving the learning and memory abilities of Alzheimer's disease (AD) model rats induced by injection of Aβ amylase into the CA1 regions of the bilateral hippocampi.

Claims

1. A Chinese medicine composition for treating Alzheimer's disease, prepared from the following raw materials in parts by weight: 5-15 parts of ginseng, 12-35 parts of rehmannia root, 9-20 parts of cornus fruit, 8-35 parts of dodder seed, 8-25 parts of eucommia barbarum, 6-15 parts of wolfberry, 9-20 parts of stir-fried spiny jujube kernel, 0.1-0.7 parts of pearl powder, 5-12 parts of calamus, 6-15 parts of poria, 5-12 parts of turmeric, and 2-8 parts of coptis root.

2. The Chinese medicine composition according to claim 1, characterized in that: The mass composition of the Chinese medicine composition is as follows: 5-12 parts of ginseng, 12-30 parts of rehmannia root, 9-18 parts of cornus fruit, 8-30 parts of dodder seed, 8-22 parts of eucommia barbarum, 6-15 parts of wolfberry, 9-15 parts of stir-fried spiny jujube kernel, 0.1-0.6 parts of pearl powder, 5-9 parts of calamus, 6-12 parts of poria, 5-10 parts of turmeric, and 2-6 parts of coptis root.

3. The Chinese medicine composition according to claim 1, characterized in that: The mass composition of the Chinese medicine composition is as follows: 6-10 parts of ginseng, 15-30 parts of rehmannia root, 10-15 parts of cornus fruit, 10-30 parts of dodder seed, 9-20 parts of eucommia barbarum, 9-12 parts of wolfberry, 9-10 parts of stir-fried spiny jujube seeds, 0.2-0.5 parts of pearl powder, 6 parts of calamus, 6-9 parts of poria, 6-9 parts of turmeric, and 3 parts of coptis root.

4. The Chinese medicine composition according to any one of claims 1 to 3, characterized in that: The mass composition of the Chinese medicine composition is any one of the following 1)-5): 1) 5 parts of ginseng, 12 parts of Rehmannia root, 9 parts of Cornus officinalis, 8 parts of Cuscuta seed, 8 parts of Morinda officinalis, 6 parts of Lycium barbarum, 9 parts of stir-fried Semen Ziziphi Spinosae, 0.1 parts of pearl powder, 5 parts of Acorus calamus, 6 parts of Poria root, 5 parts of Curcuma longa, 2 parts of Coptis chinensis; 2) 6 parts of ginseng, 15 parts of Rehmannia root, 10 parts of Cornus officinalis, 10 parts of Cuscuta seed, 9 parts of Morinda officinalis, 9 parts of Lycium barbarum, 9 parts of stir-fried Ziziphus jujuba seeds, 0.2 parts of pearl powder, 6 parts of Acorus calamus, 6 parts of Poria, 6 parts of Curcuma longa, 3 parts of Coptis chinensis; 3) 10 parts of ginseng, 30 parts of Rehmannia root, 15 parts of Cornus officinalis, 30 parts of Cuscuta seed, 20 parts of Morinda officinalis, 12 parts of Lycium barbarum, 10 parts of stir-fried Semen Ziziphi Spinosae, 0.5 parts of pearl powder, 6 parts of Acorus calamus, 9 parts of Poria, 9 parts of Curcuma longa, 3 parts of Coptis chinensis; 4) 12 parts of ginseng, 30 parts of Rehmannia root, 18 parts of Cornus officinalis, 30 parts of Cuscuta seed, 22 parts of Morinda officinalis, 15 parts of Lycium barbarum, 15 parts of stir-fried Semen Ziziphi Spinosae, 0.6 parts of pearl powder, 9 parts of Acorus calamus, 12 parts of Poria, 10 parts of Curcuma longa, and 6 parts of Coptis chinensis; 5) 15 parts of ginseng, 35 parts of prepared rehmannia root, 20 parts of cornus fruit, 35 parts of dodder seed, 25 parts of eucommia barbata, 15 parts of wolfberry, 20 parts of stir-fried spiny jujube seeds, 0.7 parts of pearl powder, 12 parts of calamus, 15 parts of poria, 12 parts of turmeric, and 8 parts of coptis root.

5. The Chinese medicine composition according to any one of claims 1 to 4, characterized in that: The dosage form of the Chinese medicine composition is granules, pills, mixtures, decoctions, syrups, decoctions, capsules or tablets.

6. A method for preparing the Chinese medicine composition according to any one of claims 1 to 5, comprising the following steps: S1, boiling Acorus calamus with water, collecting volatile oil, adding β-cyclodextrin aqueous solution for inclusion to obtain volatile oil inclusion compound; filtering the residue to obtain liquid A; S2, extracting ginseng and turmeric with an ethanol solution to obtain an ethanol extract B and medicinal residues; S3, combining Radix Rehmanniae Preparata, Fructus Corni, Semen Cuscutae, Fructus Morindae Officinalis, Fructus Lycii, stir-fried Semen Ziziphi Spinosae, Poria, Rhizoma Coptidis with the residues obtained in step S2, then decocting with water, filtering to obtain a filtrate, and concentrating the filtrate to obtain a water extract C; S4, the water extract C, the alcohol extract B and the medicinal solution A are combined and concentrated to obtain a concentrated solution D; the concentrated solution D is obtained by any one of the following steps 1)-3): 1) mixing the concentrated solution D with the volatile oil inclusion compound and pearl powder to obtain a decoction or a decoction paste; 2) The concentrated solution D is mixed with the volatile oil, pearl powder and auxiliary materials to obtain a syrup or a mixture; 3) The concentrated liquid D is dried, or dried after adding auxiliary materials, to obtain dry paste powder; the dry paste powder is mixed with the volatile oil inclusion compound and pearl powder, and auxiliary materials are added to obtain granules, capsules, tablets or pills.

7. The preparation method according to claim 6, characterized in that: In step S1, the amount of water used is 10 to 20 times the mass of the Acorus calamus; In step S2, the volume fraction of the ethanol solution is 50-80%, and the amount thereof is 6-12 times the total mass of the ginseng and the turmeric; In step S3, the amount of water is 6 to 12 times the total amount of the Radix Rehmanniae Preparata, the Fructus Corni, the Semen Cuscutae, the Fructus Morindae Officinalis, the Fructus Lycii, the stir-fried Semen Ziziphi Spinosae, the Poria, the Rhizoma Coptidis and the medicinal residues; In step S4, the relative density of the concentrated solution D is 1.03-1.

20.

8. Use of the Chinese medicine composition according to any one of claims 1 to 5 in the preparation of a medicament for preventing and / or treating Alzheimer's disease.

9. A drug for preventing and / or treating Alzheimer's disease, wherein the active ingredient is the Chinese medicine composition according to any one of claims 1 to 5.

Citation Information

Patent Citations

  • Medicine for treating senile dementia and preparing method thereof

    CN101229349A

  • Prescription and preparation method of rejoicing powder having new dosage form

    CN102895432A

  • Memory aging resistance nature drug compound prescription

    CN103316207A

  • Medicinal composition for treating Alzheimer's disease and preparation method and application of medicinal composition

    CN106692551A

  • Traditional Chinese medicinal composition for treating alzheimer disease and preparation method thereof

    CN111110749A